Roivant Sciences Reports Financial Results for the Second Quarter Ended September 30, 2022 and Provides Business Update
November 14, 2022 07:00 ET
|
Roivant Sciences
Expected cash runway extended into the second half of calendar year 2025First major PBM/payer contract signed for VTAMA, effective October 1Over 54,000 VTAMA prescriptions written by approximately...
Affivant to Present Data on AFVT-2101 at 37th Annual Meeting of SITC
November 10, 2022 09:00 ET
|
Roivant Sciences
NEW YORK and BASEL, Switzerland, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Affivant, a biotechnology company dedicated to developing novel immune-oncology approaches to activate and enable the innate immune...
Roivant Sciences Announces Pricing of Primary and Secondary Public Equity Offering
November 08, 2022 06:15 ET
|
Roivant Sciences
BASEL, Switzerland and LONDON and NEW YORK and BOSTON, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Roivant Sciences Ltd. (Nasdaq: ROIV), a next-generation biopharmaceutical company dedicated to improving the...
Roivant Sciences Announces Proposed Public Equity Offering
November 07, 2022 16:01 ET
|
Roivant Sciences
BASEL, Switzerland, LONDON, NEW YORK, and BOSTON, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Roivant Sciences Ltd. (Nasdaq: ROIV), a next-generation biopharmaceutical company dedicated to improving the...
Roivant Sciences to Report Financial Results for the Second Quarter Ended September 30, 2022 on Monday, November 14, 2022 and Present at Upcoming Conferences
October 18, 2022 16:00 ET
|
Roivant Sciences
Investor call and webcast scheduled for Monday, November 14 at 8:00 a.m. ESTRoivant will present at investor conferences in November BASEL, Switzerland and LONDON and NEW YORK and BOSTON, Oct. ...
Roivant to Participate in September Investor Events
August 30, 2022 07:00 ET
|
Roivant Sciences
Three healthcare investor conferences in September across Boston, New York and LondonRoivant Investor Day will take place virtually on September 28th starting at 11 a.m. EDT BASEL, Switzerland and...
Roivant Sciences Reports Financial Results for the First Quarter Ended June 30, 2022 and Provides Business Update
August 15, 2022 07:00 ET
|
Roivant Sciences
Early launch data for VTAMA® (tapinarof) with approximately 14,000 prescriptions written by more than 3,000 unique prescribers in initial eleven weeks of launch shows strong demand for first topical...
Roivant Sciences to Report Financial Results for the Quarter Ended June 30, 2022 on Monday, August 15, 2022
August 03, 2022 07:00 ET
|
Roivant Sciences
Investor call and webcast scheduled for Monday, August 15 at 8:00 a.m. EDTRoivant will host an investor day on Wednesday, September 28 at 11:00 a.m. EDT BASEL, Switzerland and LONDON and NEW YORK and...
Roivant Sciences Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2022 and Provides Business Update
June 28, 2022 06:10 ET
|
Roivant Sciences
Potential blockbuster VTAMA® (tapinarof) approved by FDA for the treatment of plaque psoriasis at end of May 2022 is the first topical novel chemical entity launched for plaque psoriasis in 25 years;...
Roivant and Pfizer Unveil Priovant Therapeutics and Ongoing Registrational Studies for Oral Brepocitinib in Dermatomyositis and Lupus
June 28, 2022 06:00 ET
|
Roivant Sciences
Brepocitinib is a potential first-in-class dual, selective inhibitor of TYK2 and JAK1; in all five placebo-controlled studies completed to date, oral brepocitinib generated statistically significant...